Investors

Investors

 

Keyword Search
 
2009 | 2008 | 2007 | 2006 | 2005
DateTitle 
11/12/09MDRNA, Inc. Receives NASDAQ Notification
BOTHELL, WA, Nov 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on November 6, 2009 it received a letter from The NASDAQ Stock Market, Inc. notifying the Company that, for ten consecutive business days, based on the Company's Market Value of Listed Securities (MVLS), it did not comply with the $50 million minimum MVLS for continued listing on The NASDAQ Global Market set forth in NASDAQ Marketplace Rule 5450(b)(3)(A). The Company has a grace period of 9... 
Printer Friendly Version
11/12/09MDRNA, Inc. Announces Third Quarter 2009 Financial Results
Highlights Third Quarter and Recent Corporate Accomplishments BOTHELL, WA, Nov 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the three- and nine-month periods ended September 30, 2009. Net loss for the third quarter of 2009 was approximately $7.0 million or $0.17 per share, compared to a net loss of approximately $16.1 million or $0.52 per share for the same period of 2008. The net loss for the nine months ended September 30, 2009 wa... 
Printer Friendly Version
11/05/09MDRNA, Inc. to Hold Third Quarter 2009 Results Conference Call on Thursday, November 12, 2009 at 4:30 pm Eastern Time
BOTHELL, WA, Nov 05, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a conference call with investors and security analysts on Thursday, November 12, 2009, at 4:30 pm Eastern Time (1:30 pm Pacific Time) to provide a business update and discuss financial results for the 3rd quarter ended September 30, 2009. To participate in the live conference call, U.S. residents should dial 866-543-6405 and international callers should dial 617-213-8897. The p... 
Printer Friendly Version
10/29/09MDRNA to Present Data on Tumor Reduction at Cancer Therapy Conference
Results Demonstrate Sustained Reduction in Liver and Bladder Tumor Growth via RNAi Mediated Knockdown of SurvivinBOTHELL, WA, Oct 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced the presentation of data related to its RNAi oncology programs at the 24th Annual Meeting of the International Society for Biological Therapy of Cancer, taking place October 28-31, 2009 at the Gaylord National Hotel and Conve... 
Printer Friendly Version
10/22/09MDRNA to Present at the 8th Annual BIO Investor Forum
BOTHELL, WA, Oct 22, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that J. Michael French, MDRNA's President and Chief Executive Officer, will deliver a corporate presentation and business update at the 8th Annual BIO Investor Forum. The presentation will take place on Thursday, October 29, 2009 at 9:00am Pacific Time (12:00pm Eastern Time) at the Palace Hotel in San Francisco, California. To acces... 
Printer Friendly Version
10/12/09MDRNA Reports UsiRNA Reduces Tumor Growth In Vivo
Demonstrates RNAi-Mediated Knockdown of Previously "Non-Druggable" Targets in Liver and Bladder Cancers BOTHELL, WA, Oct 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today presented new in vivo data demonstrating continued progress in the advancement of the Company's oncology program. J. Michael French, President and CEO, reported that MDRNA's UsiRNAs, delivered by the Company's DiLA2 platform, down-regulated... 
Printer Friendly Version
09/29/09MDRNA Announces Patent Allowance Covering an siRNA With Therapeutic Potential for Oncology and Other Indications
siRNA Directed Against JAM-1 Gene Also Has Potent Drug Delivery Potential BOTHELL, WA, Sep 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 11/624,630 covering an siRNA directed against a junctional adhesion molecule-1 (JAM-1) gene. The siRNA of the allowed claim has a broad array of pot... 
Printer Friendly Version
09/08/09MDRNA Adds June D. Ameen to Management Team as Vice President, Corporate Development
BOTHELL, WA, Sep 08, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that June D. Ameen, RN, MBA, will join the Company as Vice President, Corporate Development reporting to the President & CEO. Ms. Ameen will lead the alliance management, business development, technology evaluation and strategic partnering efforts for the Company. "We are extremely pleased to have June join our management team," said Michael French, President and CEO at MDRNA. "Recently, we enga... 
Printer Friendly Version
09/03/09MDRNA, Inc. to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
MDRNA to Also Participate on a Panel of Leading RNAi Companies BOTHELL, WA, Sep 03, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will present at the Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009, at 9:10 a.m. Eastern Time (6:10 a.m. Pacific Time) at the New York Palace Hotel in New York City. J. Michael French, MDRNA's President and Chief Executive Officer, will present a corporate overview and business updat... 
Printer Friendly Version
08/11/09MDRNA, Inc. Appoints James M. Karis to Its Board of Directors
BOTHELL, WA, Aug 11, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that James M. Karis has been appointed to the Company's Board of Directors. His appointment brings the number of MDRNA board members to six. "I am pleased to welcome James Karis to MDRNA's Board of Directors," stated Bruce R. Thaw, Chairman of the Board of Directors. "James has spent 30 years in the pharmaceutical, healthcare services and medical device industries and brings extensive corporate ... 
Printer Friendly Version
08/06/09MDRNA, Inc. to Present at the 29th Canaccord Adams Global Growth Conference
BOTHELL, WA, Aug 06, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will present at the 29th annual Canaccord Adams Global Growth Conference on Wednesday, August 12, 2009, at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time) at the InterContinental Hotel in Boston, Massachusetts. J. Michael French, MDRNA's President and Chief Executive Officer, will present a corporate overview and business update. To access the live audio webcast for this conference, pl... 
Printer Friendly Version
08/03/09MDRNA, Inc. Reports Positive In Vivo Data Demonstrating That Its UsiRNAs Are Highly Potent Against Metabolic and Oncology Targets
UsiRNAs Work Via the RNAi Mechanism of Action but With Minimal Off-Target Activity BOTHELL, WA, Aug 03, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today positive data on its proprietary UsiRNA technology, demonstrating that its UsiRNAs are highly potent against metabolic disease and cancer targets in rodent models. Further, the data establish that the knockdown of these targets is achieved via an RNAi-mediated process. Of particular importance is that the data ... 
Printer Friendly Version
07/29/09MDRNA, Inc. Announces Second Quarter 2009 Financial Results
BOTHELL, WA, Jul 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the three- and six-month periods ended June 30, 2009. Net loss for the second quarter of 2009 was approximately $7.5 million or $0.21 per share, compared to a net loss of approximately $14.3 million or $0.48 per share for the same period of 2008. The net loss for the six months ended June 30, 2009 was approximately $0.3 million or $0.01 per share, compared to approximately $... 
Printer Friendly Version
07/29/09MDRNA, Inc. to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference
BOTHELL, WA, Jul 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on Wednesday, August 5, 2009, at 2:15 p.m. Eastern Time (11:15 a.m. Pacific Time) at the Millennium Broadway Hotel in New York City. J. Michael French, MDRNA's President and Chief Executive Officer, will present a corporate overview and business update. To access the live audio webcast for this conference,... 
Printer Friendly Version
07/23/09MDRNA, Inc. to Hold Second Quarter 2009 Results Conference Call on Thursday, July 30, 2009, at 8:30 a.m. Eastern Time
BOTHELL, WA, Jul 23, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a conference call with investors and security analysts on Thursday, July 30, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to provide a business update and discuss financial results for the 2nd quarter ended June 30, 2009. To participate in the live conference call, U.S. residents should dial 800-510-9836 and international callers should dial 617-614-3670. The partic... 
Printer Friendly Version
07/14/09MDRNA Appoints New Chief Financial Officer
BOTHELL, WA, Jul 14, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today the appointment of Peter S. Garcia as Chief Financial Officer and Secretary, reporting to the President and CEO. Mr. Garcia will lead and direct corporate financial and financing activities, investor and public relations efforts, as well as facilities and information technology operations for the Company. "We are extremely pleased to add an individual of Pete's caliber to our management team,"... 
Printer Friendly Version
06/23/09MDRNA, Inc. Regains Full Compliance With All Marketplace Rules to Remain on the NASDAQ Global Market
Receives Letter From NASDAQ Regarding Compliance With NASDAQ Marketplace Rule 5450(b)(2)(A)BOTHELL, WA, Jun 23, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on June 22, 2009, it received a letter from The NASDAQ Stock Market, LLC notifying the Company that it has regained full compliance with all requirements for remaining on The NASDAQ Global Market, specifically NASDAQ Marketplace Rule 5450(b)(2) (the "market value standard"), which requires, among othe... 
Printer Friendly Version
06/19/09MDRNA, Inc. Gains Full Financial and Transactional Control of Its Proprietary UNA Technology
Amends Agreement With RiboTask to Eliminate All Milestone and Royalty PaymentsBOTHELL, WA, Jun 19, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it now has full financial and transactional control over the use of its proprietary UNA (Unlocked Nucleobase Analog) technology for the development of RNAi-based therapeutics. The Company completed negotiations with RiboTask ApS to eliminate all downstream financial consideration to RiboTask resulting from collabo... 
Printer Friendly Version
06/16/09MDRNA, Inc. Announces Full Repayment of GE Capital Debt
BOTHELL, WA, Jun 16, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has repaid all of its remaining debt to General Electric Capital Corporation (GECC) under the January 2009 Loan and Security Agreement. "I am pleased we have met our commitment to shareholders to eliminate the Company's remaining term debt obligations prior to the start of the third quarter," stated J. Michael French, President and CEO. "In less than five months time, we retired a $5.5 m... 
Printer Friendly Version
06/12/09MDRNA, Inc. Announces Closing of $10.5 Million Registered Direct Financing
BOTHELL, WA, Jun 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has closed its previously announced sale of 5.25 million shares of its common stock and warrants to purchase 5.25 million shares of its common stock for gross proceeds of $10.5 million. MDRNA sold the shares for $2.00 per share. The exercise price of the warrants is $2.38 per share. The warrants, with a five and a half year term, will be exercisable six months from June 12, 2009. MDRNA p... 
Printer Friendly Version
06/11/09MDRNA, Inc. Granted Request to Remain Listed on The NASDAQ Global Market
BOTHELL, WA, Jun 11, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on Wednesday, June 10, 2009, the NASDAQ Hearings Panel granted the request of the Company to remain listed on The NASDAQ Global Market and that the Company had until August 31, 2009 to establish a minimum $10.0 million in stockholders' equity or demonstrate compliance with one of the alternative listing criteria per NASDAQ Marketplace Rule 5450(b). The Company announced on March 6, 2009 tha... 
Printer Friendly Version
06/10/09MDRNA, Inc. Raises $10.5 Million in Registered Direct Offering
BOTHELL, WA, Jun 10, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it entered into definitive agreements on June 9, 2009 with existing investors to raise gross proceeds of $10.5 million though a registered direct offering. Under terms of the agreements, the Company will sell 5.25 million shares of its common stock at $2.00 per share. As part of the transaction, the investors also will receive warrants, with a five and a half year term, to purchase 5.25 mil... 
Printer Friendly Version
06/09/09MDRNA, Inc. Receives Full FDA Approval of Generic Calcitonin-Salmon Nasal Spray for Osteoporosis
Par Pharmaceutical Companies, Inc. Launches ProductBOTHELL, WA, Jun 09, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has obtained full U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray for the treatment of osteoporosis and that Par Pharmaceutical Companies, Inc. (NYSE: PAR) has launched the product. Calcitonin-salmon nasal spray, a legacy product developed by MDRNA i... 
Printer Friendly Version
06/08/09MDRNA, Inc. Reports Effective Local Delivery of a UsiRNA in an In Vivo Model of Bladder Cancer
Improved Performance of the DiLA2 siRNA Delivery Platform With Proprietary Peptide NanoparticlesBOTHELL, WA, Jun 08, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today in vivo data from a bladder cancer model demonstrating effective localized delivery of a UsiRNA to a solid tumor, thus further expanding the delivery capabilities of the DiLA2 Platform. In addition, the Company reported in vivo data demonstrating the ability of its proprietary peptide-based nanoparticl... 
Printer Friendly Version
05/26/09MDRNA, Inc. Regains Compliance With NASDAQ Marketplace Rule 5450(a)(1)
BOTHELL, WA, May 26, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has received a letter from the Listing Qualifications Department of The NASDAQ Stock Market notifying the Company that because the closing bid price of its common stock has been at or above $1.00 per share for at least ten consecutive trading days, it has regained compliance with NASDAQ Marketplace Rule 5450(a)(1) (formerly Marketplace Rule 4450(a)(5)). "We are pleased to have regained c... 
Printer Friendly Version
05/21/09MDRNA, Inc. Resizes Board of Directors
BOTHELL, WA, May 21, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that as a result of its 2009 annual meeting on May 20, 2009, it has resized its Board of Directors to establish a five person Board consistent with the Company's cost containment efforts and overall focus as an RNAi drug discovery and pre-clinical biotech company. The new Board of Directors, effective immediately, will consist of Bruce R. Thaw, Esq., Chairman of the Board; Daniel Peters; James E... 
Printer Friendly Version
05/19/09MDRNA Reports Its Proprietary RNAi-Based Compounds Are Well Tolerated and Demonstrate High Potency Against Multiple Targets in Preclinical Studies
Data Confirm 90% Knockdown of Factor VII at 1 mg/kg With Duration of Effect up to 28 DaysBOTHELL, WA, May 19, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today positive in vivo efficacy data showing that its proprietary UsiRNA constructs are highly potent and highly specific against ApoB and Factor VII message. The data are being presented today by Michael V. Templin, Ph.D., Vice President, Discovery Research and Pharmaceutical Development of MDRNA, at the TIDES Oli... 
Printer Friendly Version
05/15/09MDRNA, Inc. Appoints Beverly L. Davidson, Ph.D. and Carl Novina, M.D., Ph.D., to Its Scientific Advisory Board
BOTHELL, WA, May 15, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today the appointment of Beverly L. Davidson, Ph.D., and Carl Novina, M.D., Ph.D., to its Scientific Advisory Board (SAB). "The appointment of these outstanding scientists and opinion leaders to our Scientific Advisory Board reflects our strong commitment to scientific excellence as a premier RNAi therapeutics company," stated Barry Polisky, Ph.D., Chief Scientific Officer. "We are particularly pleas... 
Printer Friendly Version
05/14/09MDRNA, Inc. Announces First Quarter 2009 Financial Results
BOTHELL, WA, May 14, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the first quarter ended March 31, 2009. "The first quarter of 2009 was a period of significant accomplishment for the Company," stated J. Michael French, President and Chief Executive Officer. "With the sale of our intranasal contract manufacturing operations in Hauppauge, N.Y. on March 31st, we completed our transition from a clinical stage delivery company to a pre-clinic... 
Printer Friendly Version
05/11/09MDRNA, Inc. to Hold First Quarter 2009 Earnings Conference Call on Friday, May 15, 2009, at 8:30 a.m. Eastern Time
BOTHELL, WA, May 11, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a conference call with investors and security analysts on Friday, May 15, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss financial results for the first quarter ended March 31, 2009. To participate in the live conference call, U.S. residents should dial 866-761-0748 and international callers should dial 617-614-2706. The participant passcode for the live co... 
Printer Friendly Version
04/10/09MDRNA, Inc. Complies With NASDAQ Marketplace Rule 4350(b)(1)(B)
BOTHELL, WA, Apr 10, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that the Company's independent registered public accounting firm included an explanatory paragraph in their opinion on the Company's financial statements included in the recently filed Annual Report on Form 10-K for the year ended December 31, 2008, relating to the Company's ability to continue as a going concern. "As we described in our fourth quarter earnings call, we expected to receive the... 
Printer Friendly Version
04/01/09MDRNA, Inc. Sells Contract Manufacturing Operation
Company Eliminates Cash Burn Related to Non-RNAi OperationsBOTHELL, WA, Apr 01, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into an Asset Purchase Agreement with Par Pharmaceutical, Inc. (NYSE: PRX) under which Par will acquire the Company's manufacturing facilities in Hauppauge, New York as well as the Company's Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray. Under the terms of the Agreement, MDRNA will ... 
Printer Friendly Version
03/24/09MDRNA, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
BOTHELL, WA, Mar 24, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the fourth quarter and year ended December 31, 2008. "Since July 2008, MDRNA has made significant strides in its transition from a clinical stage intranasal drug delivery company to an RNAi drug discovery company," stated J. Michael French, President & CEO of MDRNA. "In the second half of 2008, we reduced headcount, terminated all legacy intranasal clinical programs; close... 
Printer Friendly Version
03/23/09MDRNA Announces Worldwide Non-Exclusive Licensing Agreement for RNAi Delivery Technology
BOTHELL, WA, Mar 23, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into a licensing agreement with Novartis for MDRNA's liposomal technology platform for siRNA delivery. MDRNA will receive $7.25 million in upfront fees for the non-exclusive license. Additionally, the companies have entered into a separate agreement, which provides Novartis with an exclusive period to negotiate a research and development collaboration and broader licensing r... 
Printer Friendly Version
03/20/09MDRNA, Inc. to Hold Year-End 2008 Earnings Conference on Tuesday, March 24, 2009, at 8:30 a.m. Eastern Time
BOTHELL, WA, Mar 20, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a conference call with investors and security analysts on Tuesday, March 24, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss financial results for the fourth quarter and fiscal year ended December 31, 2008. To participate in the live conference call, U.S. residents should dial 866-356-4441 and international callers should dial 617-597-5396. The participant ... 
Printer Friendly Version
03/06/09MDRNA, Inc. Receives Delisting Notice From NASDAQ and Requests Hearing
BOTHELL, WA, Mar 06, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it received a NASDAQ Staff Determination on March 4, 2009 indicating that the Company has not regained compliance with Marketplace Rule 4450(a)(3) within the extension period granted to the Company through March 3, 2009. Marketplace Rule 4450(a)(3) requires a minimum $10.0 million in stockholders' equity for continued listing on The NASDAQ Global Market. In response to the March 4th letter... 
Printer Friendly Version
02/23/09MDRNA Successfully Silences Gene Targets in Animal Models Using Novel UsiRNA Constructs
Proprietary DiLA2 Platform Achieves In Vivo Knockdown of Multiple Metabolic Targets and Demonstrates Safe and Effective Delivery in Repeat Dose StudiesBOTHELL, WA, Feb 23, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today positive in vivo efficacy data on its proprietary UsiRNA constructs demonstrating a dose response which resulted in up to 90% knockdown of ApoB message in a rodent model. The data were presented by Michael V. Templin, Ph.D., Vice President, Discove... 
Printer Friendly Version
02/13/09MDRNA, Inc. Announces Licensing Agreement With Roche
BOTHELL, WA, Feb 13, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into an agreement with Roche (SWX: ROG) in which Roche will obtain a non-exclusive license to a portion of MDRNA's technology platform for the development of RNAi-based therapeutics. Terms of the agreement were not disclosed. "We are pleased to have Roche recognize the value of our drug discovery platform," stated J. Michael French, President and Chief Executive Officer of ... 
Printer Friendly Version
02/03/09MDRNA, Inc. Announces Receipt of Milestone Payment Under Amended Agreement With Amylin Pharmaceuticals, Inc. for Development and Commercialization of Intranasal Exenatide
MDRNA Continues to Monetize Intranasal Assets to Support On-Going RNAi-Based Therapeutic R&DBOTHELL, WA, Feb 03, 2009 (MARKET WIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today the achievement of a milestone under an amended version of the June 2006 Development and License Agreement with Amylin Pharmaceuticals, Inc. for the development of intranasal exenatide. Under terms of the amended agreement, Amylin has committed to advancing the program, resulting in an accelerated $1 mill... 
Printer Friendly Version


  © 2008 MDRNA  Legal Notice
Home  Site Map  Contact     Search  

built@zoomedia